Labelling chemistry and characterization of [90Y/ 177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma

Marc André Fortin, Anna Orlova, Per Uno Malmström, Vladimir Tolmachev

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)


The direct instillation of radiolabelled conjugates in the urinary bladder is a promising path for the treatment of bladder carcinoma. The targeting of HER2/neu receptors expressed on the surface of many bladder carcinoma cells shows potential to be developed as a therapeutic strategy, and patients identified with a high risk of progression may benefit from adjuvant targeted radionuclide therapy. A phage-display selected Affibody molecule (Z HER2:342) which binds to HER2/neu with picomolar affinity, can be used for targeting HER2/neu-expressing bladder carcinomas. A DOTA-derivative of ZHER2:342, designated as DOTA-ZHER2:342-3, is considered as a suitable targeting agent for therapy. The DOTA chelator provides stable labelling with radiometals, and the low molecular weight (7.2 kDa) of the DOTA-ZHER2:342-3 compound is expected to enable efficient tumor penetration. DOTA-ZHER2:342-3 was radiolabelled with 90Y and 177Lu in 1 M ammonium acetate buffer, at pH 5.5, and in the presence of ascorbic acid. Nearly quantitative labelling yields were achieved for both nuclides after 15 min of incubation at 60°C. After chelation, the conjugates retained their capacity to specifically bind to HER2/neu-expressing SKOV-3 cells. The radiolabelled affibody conjugate (DOTA-ZHER2:342-3) demonstrated high antigen-binding capacity and good cellular retention. Biodistribution in normal mice demonstrated low uptake in all organs and tissues except for kidneys.

Original languageEnglish
Pages (from-to)285-291
Number of pages7
JournalInternational Journal of Molecular Medicine
Issue number2
Publication statusPublished - Feb 2007
Externally publishedYes


  • Affibody ligand
  • Bladder cancer
  • Direct instillation
  • HER2
  • Radiolabelling
  • SKOV-3

ASJC Scopus subject areas

  • Genetics

Fingerprint Dive into the research topics of 'Labelling chemistry and characterization of [<sup>90</sup>Y/ <sup>177</sup>Lu]-DOTA-Z<sub>HER2:342</sub>-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma'. Together they form a unique fingerprint.

Cite this